{"filing":{"accession_number":"0001193125-26-338054","cik":"0001953530","ticker":"OCSAW","company_name":"Oculis Holding AG","form":"6-K","filing_date":"2026-08-06","report_date":"2026-06-30","primary_document":"ocs-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1953530/000119312526338054/ocs-20260630.htm"},"events":[{"id":24571,"run_id":22278,"accession_number":"0001193125-26-338054","anchor_item_number":"EX-99.3","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Oculis Holding AG reported Q2 2026 financial results, including condensed consolidated financial statements showing a cash position of $282.3 million and detailed operating expenses. The earnings announcement includes balance sheet and income statement data typical of a quarterly financial results disclosure.","company_name":"Oculis Holding AG","ticker":"OCSAW","filing_date":"2026-08-06","form":"6-K","submitted_at":null,"items":[{"id":25173,"accession_number":"0001193125-26-338054","item_number":"EX-99.3","item_title":"ocs-ex99_3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing Q2 2026 financial results for Oculis Holding AG, including condensed consolidated financial statements (balance sheet and income statement), cash position of $282.3 million, and operating expenses. The document explicitly states \"Oculis Reports Q2 2026 Financial Results\" and includes detailed financial tables and metrics typical of a quarterly earnings announcement. While it also discusses clinical development progress, the primary disclosure is the quarterly financial results.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:12:52.664978+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25171,"accession_number":"0001193125-26-338054","item_number":"EX-99.1","item_title":"ocs-ex99_1.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":true,"confidence":0.95,"reasoning":"This exhibit is an unaudited condensed consolidated interim financial report for the six months ended June 30, 2026, prepared in accordance with IAS 34 - Interim Financial Reporting. It includes statements of financial position, loss, comprehensive loss, changes in equity, and cash flows for the interim period, along with supporting notes. This is a periodic interim financial report, not a discrete event or earnings release press announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:12:52.664978+00:00","company_name":"Oculis Holding AG","ticker":"OCSAW","filing_date":"2026-08-06"},{"id":25172,"accession_number":"0001193125-26-338054","item_number":"EX-99.2","item_title":"ocs-ex99_2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is a Management's Discussion and Analysis (MD\u0026A) accompanying unaudited condensed consolidated interim financial statements for the three and six months ended June 30, 2026, prepared under IFRS IAS 34. The document explicitly references \"Unaudited Condensed Consolidated Interim Financial Statements as of and for the three and six months ended June 30, 2026\" as Exhibit 99.1, and this MD\u0026A is the standard narrative disclosure accompanying those interim statements. This is a periodic interim financial report, not a discrete event or earnings release press announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:12:52.664978+00:00","company_name":"Oculis Holding AG","ticker":"OCSAW","filing_date":"2026-08-06"},{"id":25173,"accession_number":"0001193125-26-338054","item_number":"EX-99.3","item_title":"ocs-ex99_3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing Q2 2026 financial results for Oculis Holding AG, including condensed consolidated financial statements (balance sheet and income statement), cash position of $282.3 million, and operating expenses. The document explicitly states \"Oculis Reports Q2 2026 Financial Results\" and includes detailed financial tables and metrics typical of a quarterly earnings announcement. While it also discusses clinical development progress, the primary disclosure is the quarterly financial results.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:12:52.664978+00:00","company_name":"Oculis Holding AG","ticker":"OCSAW","filing_date":"2026-08-06"},{"id":25174,"accession_number":"0001193125-26-338054","item_number":"EX-99.4","item_title":"ocs-ex99_4.htm","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This exhibit is a summary of risk factors disclosed in a Form 6-K filing by Oculis Holding AG. It is a standard risk-disclosure section that enumerates principal risks to the business (limited operating history, accumulated losses of CHF 422.7 million, drug development uncertainty, financing needs, regulatory approval risks, etc.). While the risks themselves are material to the company's prospects, this is a routine disclosure of known risks rather than a discrete material event that would change the total mix of information available to investors. Risk factor summaries are administrative compliance disclosures, not event-driven announcements of new developments, executive changes, financial results, or other triggering events.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:12:52.664978+00:00","company_name":"Oculis Holding AG","ticker":"OCSAW","filing_date":"2026-08-06"}]}